
  
    
      
        Introduction_NNP
        With_IN the_DT exception_NN of_IN counting_VBG deaths_NNS from_IN all_DT causes_NNS ,_, a_DT
        common_JJ problem_NN in_IN clinical_JJ trials_NNS is_VBZ the_DT missing_VBG data_NN
        caused_VBN by_IN patients_NNS who_WP do_VBP not_RB complete_VB the_DT study_NN in_IN full_JJ
        schedule_NN and_CC drop_NN out_IN of_IN the_DT study_NN without_IN further_JJ
        measurements_NNS ._. Possible_JJ reasons_NNS for_IN patients_NNS dropping_VBG out_IN of_IN
        the_DT study_NN (_( the_DT so-called_NN '_POS withdrawals_NNS '_POS )_) include_VBP death_NN ,_,
        adverse_JJ reactions_NNS ,_, unpleasant_JJ study_NN procedures_NNS ,_, lack_NN of_IN
        improvement_NN ,_, early_JJ recovery_NN ,_, and_CC other_JJ factors_NNS related_VBN or_CC
        unrelated_JJ to_TO trial_NN procedure_NN and_CC treatments_NNS ._. Missing_NNP data_NNS
        in_IN a_DT study_NN because_IN of_IN dropouts_NNS may_MD cause_VB the_DT usual_JJ
        statistical_JJ analysis_NN for_IN complete_JJ or_CC available_JJ data_NNS to_TO be_VB
        subject_JJ to_TO a_DT potential_JJ bias_NN ._. This_DT review_NN attempts_NNS to_TO raise_VB
        the_DT awareness_NN of_IN the_DT problem_NN and_CC to_TO provide_VB some_DT general_JJ
        guidance_NN to_TO clinical_JJ trial_NN practitioners_NNS ._.
      
      
        Examples_NNS
        
          Example_NN 1_CD
          A_DT multicenter_NN ,_, randomized_JJ ,_, double-blind_JJ ,_, three_CD
          parallel_JJ groups_NNS trial_NN to_TO compare_VB placebo_NN ,_, candesartan_NN
          ciltexetil_NN and_CC enalapril_NN in_IN patients_NNS with_IN mild_JJ to_TO
          moderate_VB essential_JJ hypertension_NN [_NN 1_CD ]_NN ._. The_DT study_NN
          randomized_JJ 205_CD to_TO treatment_NN ,_, however_RB ,_, only_RB 178_CD patients_NNS
          were_VBD evaluable_JJ by_IN protocol_NN at_IN the_DT end_NN of_IN an_DT 8_CD -_: week_NN
          treatment_NN period_NN ._. '_POS The_DT remaining_VBG patients_NNS were_VBD excluded_VBN
          from_IN the_DT analysis_NN of_IN blood_NN pressure_NN (_( BP_NNP )_) data_NNS because_IN of_IN
          major_JJ protocol_NN violations_NNS ,_, poor_JJ compliance_NN with_IN medical_JJ
          visits_NNS ,_, or_CC withdrawal_NN because_IN of_IN adverse_JJ events_NNS ._. '_''
        
        
          Example_NN 2_CD
          A_DT multicenter_NN ,_, randomized_JJ ,_, open-label_JJ ,_, parallel-design_JJ
          study_NN to_TO compare_VB the_DT treatment_NN effect_NN of_IN niacin_NN and_CC
          atorvastatin_NN (_( for_IN 12_CD weeks_NNS )_) on_IN lipoprotein_NN subfractions_NNS
          in_IN patients_NNS with_IN atherogenic_JJ dyslipidemia_NN [_NN 2_CD ]_NN ._. '_POS Of_IN the_DT
          total_JJ 108_CD patients_NNS randomized_JJ to_TO treatment_NN ,_, 12_CD withdrew_VBD
          from_IN the_DT study_NN ._. Of_IN those_DT who_WP withdrew_VBD ,_, nine_CD were_VBD due_JJ to_TO
          adverse_JJ events_NNS ,_, two_CD were_VBD lost_VBN to_TO follow-up_JJ ,_, and_CC one_CD did_VBD
          not_RB return_VB for_IN the_DT final_JJ visit_NN ._. '_''
        
        
          Example_NN 3_CD
          A_DT multicenter_NN ,_, randomized_JJ ,_, double-blind_JJ ,_,
          placebo-controlled_JJ trial_NN to_TO assess_VB treatment_NN effect_NN of_IN
          pimobendan_NN on_IN exercise_NN capacity_NN in_IN patients_NNS with_IN chronic_JJ
          heart_NN failure_NN [_NN 3_CD ]_NN ._. '_POS The_DT primary_JJ pre-specified_JJ analysis_NN
          of_IN exercise_NN time_NN was_VBD limited_VBN to_TO those_DT patients_NNS who_WP had_VBD at_IN
          least_JJS the_DT first_JJ follow_VB up_RB (_( four-week_JJ )_) exercise_NN test_NN
          carried_VBD out_IN and_CC had_VBD shown_VBN good_JJ compliance_NN up_IN to_TO the_DT day_NN
          of_IN the_DT test_NN ._. If_IN subsequent_JJ tests_NNS were_VBD not_RB performed_VBN ,_,
          whatever_WDT the_DT reason_NN ,_, or_CC performed_VBD although_IN compliance_NN
          between_IN tests_NNS had_VBD been_VBN poor_JJ ,_, the_DT last_JJ exercise_NN time_NN value_NN
          obtained_VBN while_IN compliance_NN was_VBD good_RB was_VBD carried_VBN forward_RB ._. '_POS
          Two_CD hundred_CD and_CC forty_NN of_IN the_DT 317_CD randomized_JJ patients_NNS had_VBD
          exercise_NN test_NN done_VBN with_IN good_JJ compliance_NN at_IN four_CD ,_, 12_CD ,_, and_CC
          24_CD weeks_NNS ._. Listed_NNP reasons_NNS (_( and_CC number_NN of_IN patients_NNS )_) for_IN
          missing_VBG exercise_NN time_NN data_NNS at_IN 24_CD weeks_NNS were_VBD :_: '_POS exercise_NN
          test_NN not_RB done_VBN due_JJ to_TO death_NN '_'' (_( n_NN =_SYM 30_CD )_) ,_, '_'' exercise_NN testing_NN
          contraindicated_JJ '_POS (_( n_NN =_SYM 9_CD )_) ,_, and_CC '_POS exercise_NN test_NN not_RB done_VBN for_IN
          other_JJ reasons_NNS '_POS (_( n_NN =_SYM 10_CD )_) ._.
        
        
          Example_NN 4_CD
          A_DT randomized_JJ ,_, double-blind_JJ study_NN to_TO compare_VB
          nifedipine-_NN GITS_NNP and_CC verapamil-_NN SR_NNP on_IN hemodynamics_NNS ,_, left_VBD
          ventricular_NN mass_NN ,_, and_CC coronary_JJ vasodilatory_NN in_IN patients_NNS
          with_IN advanced_JJ hypertension_NN [_NN 4_CD ]_NN ._. Fifty-four_NNP patients_NNS
          were_VBD randomized_JJ after_IN the_DT placebo_NN run-in_JJ phase_NN ._.
          '_POS Twenty-four_CD failed_VBD to_TO complete_VB the_DT (_( six-month_JJ )_) trial_NN ,_,
          and_CC thus_RB were_VBD not_RB included_VBN for_IN analysis_NN because_IN of_IN 1_LS )_)
          withdrawal_NN for_IN symptomatic_JJ adverse_JJ effects_NNS ,_, 2_LS )_) lack_NN of_IN
          response_NN ,_, and_CC 3_LS )_) poor_JJ compliance_NN ._. '_POS '_POS Consequently_RB ,_, there_EX
          were_VBD 30_CD subjects_NNS with_IN sufficient_JJ data_NNS sets_NNS for_IN inclusion_NN
          in_IN analyses_NNS ._. '_''
        
        
          Example_NN 5_CD
          A_DT randomized_JJ ,_, double-blind_JJ ,_, titration_NN study_NN of_IN
          omapatrilat_NN with_IN hydrochlorothiazide_NN in_IN comparison_NN with_IN
          hydrochlorothiazide_NN (_( HCTZ_NNP )_) plus_CC placebo_NN for_IN the_DT treatment_NN
          of_IN hypertension_NN [_NN 5_CD ]_NN ._. After_IN 2_CD weeks_NNS of_IN placebo_NN lead_NN in_IN
          and_CC four_CD weeks_NNS of_IN HCTZ_NNP period_NN ,_, 274_CD subjects_NNS were_VBD
          randomized_JJ into_IN three_CD treatment_NN groups_NNS ._. '_POS A_DT total_NN of_IN 235_CD
          subjects_NNS completed_VBD the_DT (_( eight-week_JJ double-blind_JJ period_NN )_)
          study_NN ._. '_''
        
      
      
        Effect_NN of_IN withdrawals_NNS on_IN the_DT data_NNS analysis_NN
        To_TO demonstrate_VB with_IN simple_JJ algebra_NN the_DT effects_NNS and_CC key_JJ
        statistical_JJ concepts_NNS surrounding_VBG missing_VBG data_NNS ,_, I_PRP use_VBP the_DT
        data_NNS from_IN Example_NN 4_CD above_IN ._. In_IN that_DT study_NN ,_, 54_CD patients_NNS were_VBD
        randomized_JJ ._. However_RB ,_, only_RB the_DT 30_CD patients_NNS who_WP completed_VBD the_DT
        trial_NN were_VBD included_VBN in_IN the_DT paper_NN 's_POS analysis_NN ._. The_DT authors_NNS
        excluded_VBN from_IN the_DT analysis_NN the_DT other_JJ 24_CD patients_NNS who_WP
        withdrew_VBD early_RB because_IN of_IN adverse_JJ effects_NNS ,_, lack_NN of_IN response_NN
        or_CC poor_JJ compliance_NN ._. Defining_VBG effective_JJ control_NN of_IN BP_NNP by_IN the_DT
        criteria_NNS of_IN either_DT maintaining_VBG diastolic_JJ blood_NN pressure_NN
        (_( DBP_NNP )_) ≤_NN 95_CD mmHg_NN or_CC achieving_VBG a_DT least_JJS ≥_NN 15_CD mmHg_NN decrease_NN in_IN
        DBP_NNP ,_, the_DT authors_NNS summarized_VBD the_DT following_JJ results_VBZ :_: '_POS Eighty_NNP
        per_IN cent_NN of_IN randomized_JJ patients_NNS completed_VBD the_DT protocol_NN with_IN
        effective_JJ control_NN of_IN BP_NNP and_CC no_DT side_NN effects_NNS ._. '_POS Obviously_RB ,_,
        the_DT authors_NNS only_RB counted_VBN 24_CD patients_NNS out_IN of_IN the_DT 30_CD
        completers_NNS and_CC obtained_VBN 80_CD %_NN and_CC ignored_VBD the_DT 24_CD patients_NNS who_WP
        dropped_VBD out_IN prior_JJ to_TO the_DT scheduled_VBN end_NN of_IN the_DT study_NN at_IN six_CD
        months_NNS ._. To_TO distinguish_VB the_DT different_JJ 24_CD patients_NNS in_IN this_DT
        example_NN ,_, we_PRP denote_NN 24_CD (_( cr_NN )_) for_IN the_DT former_JJ and_CC 24_CD (_( d_SYM )_) for_IN the_DT
        latter_NN ,_, that_WDT is_VBZ ,_, dropouts_NNS ._. It_PRP is_VBZ easily_RB seen_VBN that_IN the_DT
        correct_JJ summary_NN should_MD be_VB 24_CD (_( cr_NN )_) /_NN 54_CD =_SYM 44_CD ._. 4_LS %_NN completed_VBD the_DT
        protocol_NN with_IN effective_JJ control_NN of_IN BP_NNP and_CC no_DT side_NN effects_NNS ,_,
        rather_RB than_IN the_DT reported_VBN 24_CD (_( cr_NN )_) /_NN 30_CD =_SYM 80_CD %_NN ._. (_( See_VB Table_NNP
        1_CD ._. )_)
        If_IN the_DT authors_NNS really_RB intended_VBN to_TO estimate_VB the_DT chance_NN
        for_IN patients_NNS to_TO have_VB effective_JJ control_NN of_IN BP_NNP with_IN no_DT side_NN
        effects_NNS with_IN the_DT study_NN therapies_NNS at_IN Month_NNP 6_CD (_( '_POS responders_NNS '_POS
        in_IN brief_JJ )_) ,_, then_RB we_PRP need_VBP to_TO do_VB more_JJR work_NN ._. First_LS ,_, the_DT
        calculation_NN should_MD always_RB use_VB 54_CD as_IN the_DT denominator_NN because_IN
        that_DT was_VBD the_DT number_NN of_IN patients_NNS randomized_JJ to_TO the_DT study_NN ;_:
        however_RB ,_, only_RB 30_CD patients_NNS had_VBD BP_NNP measurement_NN at_IN Month_NNP 6_CD ;_: of_IN
        them_PRP ,_, 24_CD (_( cr_NN )_) were_VBD responders_NNS ._. This_DT means_VBZ that_IN the_DT true_JJ
        answer_NN should_MD be_VB (_( 24_CD (_( cr_NN )_) +_NN ?_. )_) /_NN (_( 30_CD +_NN 24_CD (_( d_SYM )_) )_) =_SYM (_( 24_CD +_NN ?_. )_) /_NN 54_CD ,_, where_WRB
        the_DT question_NN mark_NN represents_VBZ the_DT unknown_JJ number_NN of_IN
        responders_NNS among_IN the_DT 24_CD (_( d_SYM )_) withdrawals_NNS counted_VBN in_IN the_DT
        denominator_NN ._. Next_JJ ,_, we_PRP calculate_VBP the_DT extreme_JJ possibilities_NNS
        as_IN (_( a_DT )_) (_( 24_CD (_( cr_NN )_) +_NN 0_CD )_) /_NN 54_CD =_SYM 44_CD ._. 4_LS %_NN and_CC (_( b_SYM )_) (_( 24_CD (_( cr_NN )_) +_NN 24_CD )_) /_NN 54_CD =_SYM
        48_CD /_NN 54_CD =_SYM 88_CD ._. 9_CD %_NN ._.
        In_IN (_( a_DT )_) we_PRP assumed_VBD that_DT none_NN of_IN 24_CD (_( d_SYM )_) withdrawals_NNS (_( 0_CD %_NN )_)
        responded_VBD ,_, while_IN in_IN (_( b_SYM )_) we_PRP assume_VBP all_DT 24_CD (_( d_SYM )_) withdrawals_NNS
        (_( 100_CD %_NN )_) responded_VBD ._. Of_IN course_NN ,_, we_PRP know_VBP that_IN (_( b_SYM )_) is_VBZ
        unrealistic_JJ since_IN some_DT people_NNS withdrew_VBD because_IN of_IN lack_NN of_IN
        response_NN and_CC some_DT because_IN of_IN side_NN effects_NNS ,_, but_CC the_DT paper_NN
        did_VBD not_RB provide_VB the_DT exact_JJ numbers_NNS ._. In_IN general_JJ ,_, we_PRP usually_RB
        do_VBP not_RB feel_VB comfortable_JJ with_IN either_DT extreme_JJ ,_, but_CC we_PRP
        understand_VBP that_IN they_PRP provide_VBP an_DT idea_NN of_IN the_DT uncertainty_NN in_IN
        the_DT data_NNS because_IN of_IN withdrawals_NNS ._.
        An_DT estimate_NN between_IN the_DT extremes_NNS is_VBZ (_( c_SYM )_) :_: to_TO substitute_VB
        the_DT unknown_JJ number_NN by_IN 24_CD (_( d_SYM )_) ×_NN (_( 24_CD (_( cr_NN )_) /_NN 30_CD )_) =_SYM 24_CD (_( d_SYM )_) ×_NN 0_CD ._. 80_CD =_SYM
        19_CD ._. 2_LS ,_, where_WRB 24_CD (_( cr_NN )_) /_NN 30_CD =_SYM 80_CD %_NN is_VBZ the_DT proportion_NN of_IN
        responders_NNS among_IN those_DT who_WP completed_VBD the_DT trial_NN ._. That_DT is_VBZ ,_,
        when_WRB no_DT particular_JJ information_NN was_VBD available_JJ ,_, we_PRP may_MD assume_VB
        that_IN the_DT same_JJ proportion_NN of_IN patients_NNS (_( 80_CD %_NN )_) among_IN the_DT 24_CD
        (_( d_SYM )_) dropouts_NNS would_MD have_VB also_RB responded_VBN ,_, had_VBD they_PRP completed_VBD
        six_CD months_NNS ._. Unsurprisingly_NNP ,_, when_WRB we_PRP do_VBP the_DT calculation_NN ,_, the_DT
        estimate_NN becomes_VBZ (_( 24_CD (_( cr_NN )_) +_NN 19_CD ._. 2_LS )_) /_NN 54_CD =_SYM 43_CD ._. 2_LS /_NN 54_CD =_SYM 80_CD %_NN ,_, the_DT
        same_JJ answer_NN as_IN that_DT using_VBG only_RB the_DT completers_NNS ._. In_IN fact_NN ,_, a_DT
        simple_JJ algebra_NN can_MD show_VB that_IN this_DT is_VBZ always_RB so_RB ._. We_PRP can_MD see_VB
        that_IN (_( c_SYM )_) is_VBZ in-between_JJ (_( a_DT )_) and_CC (_( b_SYM )_) ,_, and_CC in_IN this_DT case_NN ,_, leans_VBZ
        toward_IN (_( b_SYM )_) ._. See_VB Table_NNP 2_CD ._.
        Notice_NNP that_IN the_DT paper_NN reported_VBD that_IN a_DT proportion_NN of_IN 80_CD %_NN
        of_IN '_POS randomized_JJ patients_NNS completed_VBD the_DT protocol_NN with_IN
        effective_JJ control_NN of_IN BP_NNP and_CC no_DT side_NN effects_NNS '_POS (_( as_IN explained_VBN
        earlier_RBR ,_, the_DT figure_NN should_MD instead_RB be_VB 44_CD ._. 4_LS %_NN )_) ,_, while_IN the_DT 80_CD %_NN
        in_IN (_( c_SYM )_) is_VBZ an_DT estimate_NN of_IN the_DT chance_NN of_IN effective_JJ control_NN of_IN
        BP_NNP without_IN side_NN effects_NNS with_IN the_DT study_NN therapies_NNS at_IN Month_NNP
        6_CD ,_, under_IN an_DT assumption_NN of_IN '_POS no_DT information_NN available_JJ for_IN the_DT
        missing_VBG data_NN '_'' ._. We_PRP should_MD not_RB be_VB confused_VBN with_IN these_DT two_CD
        '_POS 80_CD %_NN '_'' ._. The_DT former_JJ 80_CD %_NN is_VBZ a_DT wrong_JJ summary_NN number_NN ;_: the_DT latter_NN
        is_VBZ an_DT estimate_NN of_IN the_DT quantity_NN of_IN interest_NN with_IN a_DT
        particular_JJ assumption_NN about_IN the_DT missing_VBG data_NN ._. This_DT
        assumption_NN is_VBZ not_RB likely_JJ to_TO be_VB appropriate_JJ for_IN all_PDT the_DT
        dropouts_NNS ,_, especially_RB for_IN those_DT patients_NNS who_WP dropped_VBD out_IN
        because_IN of_IN ineffective_JJ therapy_NN ;_: more_JJR discussion_NN is_VBZ given_VBN
        later_RB ._. We_PRP do_VBP not_RB know_VB whether_IN the_DT authors_NNS might_MD have_VB
        intended_VBN to_TO make_VB the_DT latter_JJ estimate_NN but_CC gave_VBD a_DT wrong_JJ
        summary_NN instead_RB ._.
        Even_RB more_RBR interesting_JJ and_CC useful_JJ would_MD be_VB the_DT same_JJ
        calculations_NNS within_IN each_DT treatment_NN group_NN along_IN with_IN a_DT
        comparison_NN of_IN the_DT estimates_NNS ._. Unfortunately_RB ,_, the_DT paper_NN did_VBD
        not_RB give_VB the_DT number_NN of_IN dropouts_NNS according_VBG to_TO their_PRP$
        treatment_NN groups_NNS ._.
        Using_VBG proportions_NNS simplifies_NNS the_DT illustration_NN ,_, but_CC the_DT
        idea_NN can_MD easily_RB be_VB conveyed_VBD to_TO the_DT estimation_NN of_IN continuous_JJ
        data_NNS as_IN well_RB ,_, such_JJ as_IN BP_NNP ,_, exercise_NN time_NN ,_, hemodynamic_JJ
        measures_NNS ,_, and_CC lipoprotein_NN levels_NNS ._.
      
      
        Lessons_NNP learned_VBD
        Several_JJ points_NNS can_MD be_VB generalized_JJ from_IN the_DT simple_JJ
        illustration_NN given_VBN above_IN and_CC closer_JJR examinations_NNS of_IN the_DT
        other_JJ examples_NNS ._.
        •_NN It_PRP does_VBZ not_RB take_VB very_RB much_RB missing_VBG data_NNS to_TO mislead_NN an_DT
        investigator_NN ._. A_DT good_JJ principle_NN to_TO avoid_VB being_VBG misled_VBN is_VBZ to_TO
        always_RB account_VB for_IN every_DT subject_JJ randomized_JJ to_TO the_DT study_NN in_IN
        the_DT analysis_NN ._. Using_VBG the_DT total_JJ number_NN of_IN randomized_JJ subjects_NNS
        in_IN the_DT denominator_NN is_VBZ a_DT step_NN towards_IN accomplishing_VBG this_DT
        principle_NN ,_, whether_IN it_PRP is_VBZ to_TO calculate_VB an_DT average_JJ or_CC a_DT
        proportion_NN ._. This_DT principle_NN is_VBZ known_VBN as_IN intent_NN to_TO treat_VB
        (_( ITT_NNP )_) ._. However_RB ,_, the_DT much_RB harder_RBR job_NN for_IN ITT_NNP is_VBZ to_TO account_VB
        for_IN the_DT dropouts_NNS in_IN the_DT numerator_NN ._. This_DT requires_VBZ further_JJ
        consideration_NN ,_, which_WDT follows_VBZ below_IN ._.
        •_NN It_PRP is_VBZ important_JJ to_TO record_VB and_CC report_VB the_DT reasons_NNS for_IN
        withdrawal_NN and_CC the_DT number_NN of_IN subjects_NNS in_IN each_DT category_NN of_IN
        withdrawal_NN according_VBG to_TO their_PRP$ treatment_NN group_NN ._. The_DT reasons_NNS
        for_IN patients_NNS dropping_VBG out_IN can_MD be_VB used_VBN to_TO help_VB properly_RB
        assess_VB the_DT nature_NN of_IN the_DT missing_VBG data_NN ._. For_IN example_NN ,_, if_IN all_PDT
        the_DT dropouts_NNS were_VBD because_IN of_IN a_DT lack_NN of_IN response_NN or_CC side_NN
        effects_NNS ,_, then_RB the_DT calculation_NN in_IN (_( a_DT )_) would_MD be_VB appropriate_JJ ._.
        In_IN statistical_JJ terms_NNS ,_, they_PRP would_MD be_VB called_VBN informative_JJ
        missing_VBG data_NNS ._. This_DT is_VBZ because_IN useful_JJ information_NN can_MD be_VB
        found_VBN in_IN the_DT reason_NN for_IN the_DT dropout_NN and_CC this_DT can_MD be_VB used_VBN to_TO
        estimate_VB the_DT true_JJ response_NN ._. Outcome-related_NNP dropouts_NNS are_VBP
        informative_JJ and_CC should_MD not_RB be_VB disregarded_VBD in_IN analytical_JJ
        study_NN without_IN careful_JJ thought_NN ._. In_IN particular_JJ ,_, when_WRB a_DT
        patient_NN dies_VBZ ,_, whatever_WDT the_DT cause_NN of_IN the_DT death_NN might_MD be_VB ,_,
        such_JJ as_IN in_IN Example_NN 3_CD ,_, all_DT of_IN the_DT subsequent_JJ physiological_JJ
        and_CC quality_NN of_IN life_NN data_NNS should_MD not_RB even_RB be_VB regarded_VBN as_IN
        missing_VBG ,_, but_CC as_IN having_VBG values_NNS equal_JJ to_TO zero_CD or_CC the_DT worst_JJS
        category_NN ._. When_WRB a_DT patient_NN 's_POS clinical_JJ status_NN has_VBZ reached_VBN a_DT
        terminal_NN disease_NN progression_NN stage_NN (_( such_JJ as_IN New_NNP York_NNP Heart_NNP
        Association_NNP class_NN IV_NNP )_) and_CC they_PRP are_VBP unable_JJ to_TO perform_VB
        exercise_NN testing_NN ,_, as_IN in_IN Example_NN 3_CD ,_, the_DT exercise_NN time_NN should_MD
        also_RB be_VB equal_JJ to_TO zero_CD seconds_NNS ,_, and_CC not_RB simply_RB regarded_VBN as_IN
        missing_VBG data_NNS ._. For_IN the_DT same_JJ reason_NN ,_, the_DT remaining_VBG survival_NN
        time_NN after_IN death_NN (_( of_IN any_DT cause_NN )_) would_MD be_VB zero_CD days_NNS as_IN well_RB ,_,
        not_RB a_DT censored_VBN observation_NN when_WRB doing_VBG ,_, say_VBP Kaplan-_NNP Meier_NNP ,_,
        survival_NN analysis_NN for_IN an_DT endpoint_NN such_JJ as_IN cardiovascular_JJ
        death_NN ._. Treating_NNP non-cardiovascular_JJ death_NN as_IN equivalent_JJ to_TO
        censoring_VBG because_IN of_IN loss-to-follow-up_JJ or_CC
        end-of-observation_JJ for_IN an_DT endpoint_NN of_IN cardiovascular_JJ death_NN
        has_VBZ unfortunately_RB become_VBN a_DT popular_JJ practice_NN in_IN many_JJ medical_JJ
        journal_NN articles_NNS ._. This_DT needs_VBZ to_TO be_VB corrected_VBN ._.
        •_NN The_DT extreme_JJ calculations_NNS in_IN (_( a_DT )_) and_CC (_( b_SYM )_) enable_VB us_PRP to_TO
        assess_VB the_DT uncertainty_NN of_IN the_DT data_NNS which_WDT contains_VBZ missing_VBG
        values_NNS ,_, especially_RB if_IN we_PRP do_VBP the_DT calculation_NN for_IN each_DT
        treatment_NN group_NN separately_RB ._. The_DT bias_NN seen_VBN in_IN the_DT medical_JJ
        publishing_NN industry_NN in_IN the_DT decisions_NNS over_IN which_WDT articles_NNS
        are_VBP chosen_VBN for_IN publication_NN is_VBZ a_DT mirror_NN image_NN of_IN the_DT dropout_NN
        problem_NN in_IN patient_NN studies_NNS ._. In_IN the_DT former_JJ ,_, positive_JJ studies_NNS
        have_VBP better_JJR chance_NN of_IN getting_VBG published_VBN ,_, while_IN negative_JJ
        studies_NNS have_VBP a_DT higher_JJR chance_NN of_IN being_VBG rejected_VBN ._. The_DT same_JJ is_VBZ
        true_JJ for_IN the_DT latter_JJ :_: patients_NNS responding_VBG to_TO treatment_NN tend_VBP
        to_TO continue_VB in_IN the_DT study_NN ,_, while_IN patients_NNS failing_VBG to_TO respond_VB
        tend_VBP to_TO drop_VB out_IN prematurely_RB ._. Using_VBG only_RB the_DT available_JJ data_NN
        or_CC only_RB the_DT subgroup_NN of_IN those_DT who_WP complete_VB the_DT study_NN leads_VBZ
        to_TO a_DT biased_VBN result_NN ._. The_DT approaches_NNS in_IN (_( a_DT )_) and_CC (_( b_SYM )_) take_VB this_DT
        consideration_NN into_IN account_NN ,_, although_IN they_PRP may_MD also_RB be_VB
        biased_VBN by_IN over-correction_JJ ._.
        •_NN The_DT assumption_NN underlying_VBG the_DT approach_NN in_IN (_( c_SYM )_) is_VBZ
        interesting_JJ ._. When_WRB no_DT particular_JJ information_NN is_VBZ known_VBN about_IN
        the_DT missing_VBG data_NN ,_, we_PRP are_VBP essentially_RB assuming_VBG that_IN the_DT
        dropouts_NNS are_VBP not_RB much_JJ different_JJ from_IN the_DT completers_NNS ._. This_DT
        is_VBZ generally_RB described_VBN statistically_RB as_IN missing_VBG completely_RB
        at_IN random_JJ (_( MCAR_NNP )_) ,_, meaning_VBG that_IN the_DT process_NN which_WDT caused_VBD the_DT
        missing_VBG data_NN is_VBZ not_RB informative_JJ about_IN the_DT parameter_NN that_IN we_PRP
        are_VBP trying_VBG to_TO estimate_VB ._. A_DT good_JJ way_NN to_TO think_VB of_IN MCAR_NNP is_VBZ that_IN
        the_DT dropouts_NNS are_VBP a_DT simple_JJ ,_, random_JJ sample_NN of_IN the_DT study_NN
        sample_NN ._. Examples_NNS of_IN MCAR_NNP include_VBP patients_NNS who_WP have_VBP moved_VBN
        away_RB ,_, or_CC study_NN that_WDT has_VBZ closed_VBN and_CC the_DT late_JJ entry_NN of_IN
        patients_NNS being_VBG administratively_RB '_POS censored_VBN '_'' ._. We_PRP have_VBP seen_VBN
        the_DT convenience_NN of_IN MCAR_NNP in_IN the_DT above_JJ illustration_NN :_: simply_RB
        use_NN the_DT completers_NNS and_CC we_PRP get_VBP the_DT same_JJ result_NN ._. However_RB ,_,
        whether_IN this_DT assumption_NN is_VBZ valid_JJ or_CC not_RB should_MD be_VB examined_VBN
        carefully_RB in_IN each_DT individual_JJ case_NN ._. In_IN many_JJ situations_NNS ,_,
        dropouts_NNS are_VBP not_RB the_DT same_JJ patient_NN population_NN as_IN those_DT who_WP
        stayed_VBD within_IN the_DT trial_NN ._. MCAR_NNP certainly_RB is_VBZ less_RBR restrictive_JJ
        than_IN the_DT assumptions_NNS in_IN (_( a_DT )_) or_CC (_( b_SYM )_) ._. Still_RB ,_, other_JJ less_RBR
        restrictive_JJ assumptions_NNS than_IN MCAR_NNP exist_VB ,_, and_CC these_DT are_VBP
        discussed_VBN later_RB ._.
        •_NN All_DT three_CD estimates_NNS given_VBN by_IN (_( a_DT )_) ,_, (_( b_SYM )_) ,_, and_CC (_( c_SYM )_) are_VBP
        biased_VBN to_TO a_DT certain_JJ extent_NN ._. Had_VBD the_DT authors_NNS given_VBN the_DT
        detail_NN about_IN the_DT numbers_NNS of_IN dropout_NN categories_NNS of_IN '_POS lack_NN of_IN
        response_NN '_'' and_CC '_POS side_NN effects_NNS '_POS ,_, a_DT better_JJR estimate_NN could_MD be_VB
        derived_VBN ._.
        •_NN We_PRP would_MD certainly_RB feel_VB more_RBR comfortable_JJ with_IN a_DT study_NN
        conclusion_NN when_WRB it_PRP is_VBZ not_RB altered_VBN by_IN different_JJ approaches_NNS ._.
        Sensitivity_NNP analysis_NN is_VBZ actually_RB the_DT best_JJS way_NN to_TO analyze_VB
        data_NNS in_IN the_DT presence_NN of_IN dropouts_NNS ._. Medical_JJ investigators_NNS
        should_MD consult_VB with_IN statisticians_NNS when_WRB dealing_VBG with_IN missing_VBG
        data_NNS because_IN there_EX are_VBP many_JJ possible_JJ methods_NNS available_JJ ._.
        Some_DT popular_JJ approaches_NNS are_VBP reviewed_VBN below_IN ._.
      
      
        More_JJR about_IN methods_NNS handling_VBG missing_VBG data_NNS
        
          Objectives_NNP
          As_IN in_IN any_DT data_NNS analysis_NN ,_, the_DT first_JJ consideration_NN is_VBZ
          the_DT objective_NN of_IN the_DT analysis_NN ._. In_IN the_DT presence_NN of_IN
          dropouts_NNS ,_, there_EX can_MD be_VB two_CD types_NNS of_IN questions_NNS :_: (_( i_NNP )_) What_WP
          would_MD be_VB the_DT treatment_NN effect_NN without_IN dropouts_NNS ?_. and_CC (_( ii_NN )_)
          What_WP would_MD be_VB the_DT treatment_NN effect_NN in_IN the_DT presence_NN of_IN
          dropouts_NNS ?_. Question_NNP (_( i_NNP )_) is_VBZ concerned_VBN with_IN an_DT ideal_JJ
          situation_NN ._. It_PRP is_VBZ also_RB known_VBN as_IN a_NNP '_POS question_NN for_IN
          explanatory_JJ trials_NNS '_POS [_NN 6_CD ]_NN ._. It_PRP is_VBZ often_RB concerned_VBN with_IN
          the_DT human_JJ pharmacological_JJ properties_NNS of_IN new_JJ drugs_NNS under_IN
          investigation_NN rather_RB than_IN practical_JJ usage_NN ._. Regarding_VBG
          question_NN (_( ii_NN )_) ,_, we_PRP need_VBP to_TO further_VB differentiate_VB two_CD
          situations_NNS :_: patients_NNS drop_VBP out_IN either_DT (_( a_DT )_) totally_RB from_IN the_DT
          study_NN and_CC no_DT data_NNS are_VBP collected_VBN after_IN withdrawal_NN ,_, or_CC (_( b_SYM )_)
          merely_RB from_IN the_DT study_NN assigned_VBN treatment_NN with_IN data_NNS still_RB
          being_VBG collected_VBN ._. For_IN (_( b_SYM )_) there_EX will_MD be_VB no_DT missing_VBG data_NN ._.
          If_IN we_PRP can_MD design_VB trials_NNS that_WDT will_MD allow_VB patients_NNS to_TO be_VB
          followed_VBN until_IN the_DT end_NN of_IN the_DT study_NN despite_IN the_DT patient_NN 's_POS
          lack_NN of_IN compliance_NN ,_, then_RB (_( ii_NN )_) is_VBZ a_DT very_RB practical_JJ
          question_NN ,_, also_RB known_VBN as_IN the_NNP '_POS question_NN for_IN pragmatic_JJ
          trials_NNS '_POS [_NN 7_CD ]_NN ._. Prevention_NNP studies_NNS with_IN all-cause_JJ
          mortality_NN as_IN the_DT primary_JJ endpoint_NN usually_RB follow_VB this_DT
          design_NN ._. However_RB ,_, other_JJ endpoints_NNS may_MD also_RB be_VB followed-up_JJ
          (_( until_IN death_NN )_) in_IN such_JJ a_DT design_NN ._. A_DT recent_JJ example_NN is_VBZ [_NN 8_CD ]_NN
          ,_, in_IN which_WDT all_DT participants_NNS ,_, even_RB those_DT who_WP discontinued_VBN
          treatment_NN (_( lovastatin_NN or_CC placebo_NN )_) ,_, were_VBD contacted_VBN
          annually_RB for_IN vital_JJ status_NN ,_, cardiovascular_JJ events_NNS ,_, and_CC
          cancer_NN history_NN ._. Since_IN no_DT missing_VBG data_NN would_MD occur_VB ,_, the_DT
          design_NN of_IN (_( b_SYM )_) is_VBZ highly_RB recommended_VBN for_IN all_DT trials_NNS if_IN at_IN
          all_DT possible_JJ ._. In_IN fact_NN ,_, the_DT ITT_NNP principle_NN originally_RB aims_VBZ
          to_TO answer_VB question_NN (_( ii_NN )_) with_IN (_( b_SYM )_) type_NN of_IN dropouts_NNS ,_, where_WRB
          no_DT missing_VBG data_NN would_MD occur_VB ._. However_RB ,_, more_RBR often_RB than_IN not_RB
          we_PRP face_VBP studies_NNS in_IN which_WDT patients_NNS have_VBP withdrawn_VBN from_IN the_DT
          study_NN entirely_RB and_CC caused_VBD the_DT missing_VBG data_NN problem_NN ,_, ie_NN ,_,
          type_NN (_( a_DT )_) ,_, as_IN the_DT Examples_NNS 1_CD -_: 5_CD (_( with_IN the_DT exception_NN of_IN
          Example_NN 3_LS )_) above_IN have_VBP demonstrated_VBN ._. Unless_IN the_DT patient_NN 's_POS
          clinical_JJ status_NN does_VBZ not_RB permit_VB further_JJ testing_NN after_IN
          discontinuing_VBG the_DT study_NN treatment_NN ,_, type_NN (_( a_DT )_) dropout_NN
          problem_NN is_VBZ a_DT common_JJ design_NN flaw_NN and_CC should_MD be_VB corrected_VBN ._.
          Nevertheless_RB ,_, the_DT problem_NN of_IN no_DT follow-up_JJ data_NN prevails_VBZ
          in_IN clinical_JJ trials_NNS ._. For_IN clinical_JJ trials_NNS conducted_VBN for_IN
          drug_NN registrations_NNS it_PRP is_VBZ possible_JJ that_IN ,_, in_IN light_NN of_IN the_DT
          International_NNP Conference_NNP on_IN Harmonization_NNP (_( ICH_NNP )_) -_: E_NNP 9_CD
          guideline_NN [_NN 9_CD ]_NN ,_, the_DT data_NNS analyses_NNS have_VBP to_TO address_VB both_DT
          questions_NNS (_( i_NNP )_) and_CC (_( ii_NN )_) ._.
        
        
          Imputation_NNP methods_NNS
          The_DT analyses_NNS illustrated_VBN in_IN Table_NNP 2_CD were_VBD methods_NNS in_IN the_DT
          general_JJ category_NN of_IN imputation_NN ._. In_IN general_JJ ,_, the_DT basic_JJ
          idea_NN of_IN imputation_NN is_VBZ to_TO fill_VB in_IN the_DT missing_VBG data_NN by_IN
          using_VBG values_NNS based_VBN on_IN a_DT certain_JJ model_NN with_IN assumptions_NNS ._.
          There_EX are_VBP methods_NNS based_VBN on_IN a_DT single_JJ imputation_NN and_CC
          methods_NNS based_VBN on_IN multiple_JJ imputation_NN ,_, which_WDT ,_, instead_RB of_IN
          filling_VBG in_IN a_DT single_JJ value_NN for_IN each_DT missing_VBG value_NN ,_, replace_VBP
          each_DT missing_VBG value_NN with_IN a_DT set_NN of_IN plausible_JJ values_NNS that_WDT
          represent_VBP the_DT uncertainty_NN about_IN the_DT right_JJ value_NN to_TO
          impute_NN ._. The_DT attraction_NN of_IN imputation_NN is_VBZ that_IN once_RB the_DT
          missing_VBG data_NN are_VBP filled-in_JJ (_( imputed_JJ )_) ,_, all_PDT the_DT statistical_JJ
          tools_NNS available_JJ for_IN the_DT complete_JJ data_NN may_MD be_VB applied_VBN ._.
          Each_DT method_NN of_IN (_( a_DT )_) ,_, (_( b_SYM )_) and_CC (_( c_SYM )_) in_IN Table_NNP 2_CD is_VBZ a_DT single_JJ
          simple_JJ imputation_NN method_NN ,_, but_CC together_RB they_PRP may_MD be_VB viewed_VBN
          as_IN a_NNP '_POS multiple_JJ simple_JJ imputation_NN '_'' method_NN (_( as_IN opposed_VBN to_TO
          the_DT '_POS proper_JJ multiple_JJ imputation_NN '_'' method_NN discussed_VBD below_IN )_) ._.
          The_DT data_NNS in_IN Table_NNP 2_CD only_RB had_VBD one_CD time-point_JJ (_( Month_NNP 6_CD )_) for_IN
          analysis_NN ._.
          For_IN longitudinal_NN data_NNS with_IN multiple_JJ time-points_JJ ,_, the_DT
          conventional_JJ last-observation-carried-forward_JJ (_( LOCF_NNP )_)
          approach_NN is_VBZ a_DT common_JJ practice_NN of_IN another_DT simple_JJ
          imputation_NN ._. This_DT approach_NN was_VBD used_VBN by_IN the_DT authors_NNS in_IN
          Examples_NNS 3_CD and_CC 5_CD ._. Attempting_NNP to_TO follow_VB the_DT principle_NN of_IN
          ITT_NNP to_TO account_VB for_IN all_DT randomized_JJ ,_, LOCF_NNP method_NN includes_VBZ
          every_DT randomized_JJ subject_JJ who_WP has_VBZ at_IN least_JJS one_CD
          post-therapy_JJ observation_NN ._. LOCF_NNP is_VBZ popular_JJ among_IN
          practitioners_NNS because_IN it_PRP is_VBZ simple_JJ to_TO put_VB into_IN effect_NN and_CC
          because_IN of_IN a_DT misconception_NN that_IN it_PRP is_VBZ conservative_JJ
          (_( meaning_VBG working_VBG against_IN an_DT effective_JJ treatment_NN group_NN )_) ._.
          However_RB ,_, every_DT imputation_NN method_NN implicitly_RB or_CC explicitly_RB
          assumes_VBZ a_DT model_NN for_IN the_DT missing_VBG data_NN ._. The_DT LOCF_NNP assumes_VBZ
          (_( unrealistically_RB )_) that_IN the_DT missing_VBG data_NN after_IN patient_NN 's_POS
          withdrawal_NN are_VBP the_DT same_JJ as_IN the_DT last_JJ value_NN observed_VBD for_IN
          that_DT patient_NN ._. The_DT consequence_NN of_IN this_DT assumption_NN is_VBZ that_IN
          it_PRP imputes_NNS data_NNS without_IN giving_VBG them_PRP within-subject_JJ
          variability_NN and_CC that_IN it_PRP alters_NNS the_DT sample_NN size_NN ._.
          Proper_JJ multiple_JJ imputation_NN (_( PMI_NNP )_) methods_NNS are_VBP described_VBN
          in_IN [_NN 10_CD ]_NN and_CC [_NN 11_CD ]_NN ,_, which_WDT use_VBP regression_NN models_NNS to_TO
          create_VB more_JJR than_IN one_CD imputed_JJ data_NNS sets_NNS and_CC thus_RB provide_VB
          variability_NN within_IN and_CC between_IN imputations_NNS ._. PMI_NNP method_NN
          has_VBZ long_RB been_VBN a_DT preferred_JJ approach_NN in_IN survey_NN research_NN ._.
          Its_PRP$ popularity_NN has_VBZ recently_RB gainied_JJ in_IN clinical_JJ trials_NNS
          since_IN the_DT method_NN became_VBD automated_VBN by_IN commercial_JJ computer_NN
          software_NN [_NN 12_CD 13_CD ]_NN ._. However_RB ,_, the_DT complexity_NN of_IN
          regression_NN models_NNS used_VBN in_IN PMI_NNP should_MD be_VB carefully_RB thought_VBN
          through_IN by_IN clinical_JJ trial_NN practitioners_NNS ,_, because_IN the_DT
          method_NN assumes_VBZ that_IN the_DT missing_VBG data_NN process_VBP can_MD be_VB fully_RB
          captured_VBN by_IN the_DT regression_NN model_NN employed_VBN on_IN observed_VBD
          values_NNS ._. This_DT assumption_NN is_VBZ called_VBN missing_VBG at_IN random_JJ
          (_( MAR_NNP )_) ._. MAR_NNP essentially_RB says_VBZ that_IN the_DT cause_NN of_IN the_DT missing_VBG
          data_NN may_MD be_VB dependent_JJ on_IN observed_VBD data_NNS (_( such_JJ as_IN data_NNS of_IN
          previous_JJ visits_NNS )_) but_CC must_MD be_VB independent_JJ of_IN the_DT missing_VBG
          value_NN that_WDT would_MD have_VB been_VBN observed_VBN ._. It_PRP is_VBZ a_DT less_RBR
          restrictive_JJ model_NN than_IN MCAR_NNP ,_, which_WDT says_VBZ that_IN the_DT missing_VBG
          data_NN cannot_NN be_VB dependent_JJ on_IN either_DT the_DT observed_VBD or_CC the_DT
          missing_VBG data_NN ._. The_DT design_NN suggested_VBN by_IN Murray_NNP and_CC Findlay_NNP
          [_NN 14_CD ]_NN ,_, which_WDT forced_VBD dropouts_NNS upon_IN observing_VBG
          uncontrolled_JJ BP_NNP ,_, uses_VBZ the_DT MAR_NNP principle_NN ._. When_WRB MAR_NNP or_CC MCAR_NNP
          conditions_NNS are_VBP met_VBN ,_, model-based_JJ analyses_NNS can_MD be_VB
          appropriately_RB performed_VBN based_VBN on_IN the_DT observed_VBN data_NN alone_RB
          without_IN further_JJ modeling_VBG the_DT missing_VBG data_NN process_VBP ._.
          Another_DT imputation_NN method_NN ,_, which_WDT is_VBZ in-between_JJ the_DT
          LOCF_NNP and_CC PMI_NNP ,_, is_VBZ the_DT partial_JJ imputation_NN (_( PI_NNP )_) or_CC improved_VBN
          LOCF_NNP method_NN [_NN 15_CD ]_NN ._. The_DT idea_NN of_IN this_DT method_NN is_VBZ quite_RB
          simple_JJ ._. In_IN LOCF_NNP ,_, one_CD imputes_NNS every_DT missing_VBG visit_NN
          time-point_JJ by_IN carrying_VBG the_DT last_JJ observation_NN forward_RB until_IN
          the_DT end_NN of_IN the_DT study_NN ._. Since_IN LOCF_NNP requires_VBZ the_DT strong_JJ
          assumption_NN of_IN stability_NN ,_, the_DT more_JJR it_PRP imputes_NNS the_DT more_JJR
          bias_NN it_PRP introduces_VBZ if_IN the_DT assumption_NN of_IN stability_NN does_VBZ
          not_RB hold_VB ._. The_DT method_NN of_IN PI_NNP does_VBZ not_RB always_RB carry_VB the_DT
          observations_NNS to_TO the_DT end_NN time-point_JJ of_IN the_DT study_NN ,_, but_CC just_RB
          far_RB enough_RB to_TO balance_VB the_DT dropout_NN patterns_NNS between_IN the_DT
          treatment_NN groups_NNS ._. The_DT underlying_VBG principle_NN is_VBZ that_IN when_WRB
          the_DT dropout_NN patterns_NNS are_VBP made_VBN almost_RB identical_JJ between_IN
          the_DT treatment_NN groups_NNS ,_, the_DT relative_JJ comparison_NN of_IN the_DT
          treatment_NN effects_NNS will_MD be_VB less_RBR biased_VBN ._. Since_IN PI_NNP does_VBZ less_JJR
          imputation_NN ,_, it_PRP is_VBZ less_RBR biased_VBN than_IN LOCF_NNP because_IN the_DT
          assumption_NN of_IN stability_NN usually_RB does_VBZ not_RB hold_VB ._. Some_DT
          simulation_NN results_NNS under_IN various_JJ missing_VBG data_NNS processes_VBZ
          demonstrated_VBN the_DT potential_JJ usefulness_NN of_IN PI_NNP over_IN the_DT
          methods_NNS of_IN using_VBG all_DT available_JJ data_NN and_CC LOCF_NNP [_NN 15_CD ]_NN ._.
          However_RB ,_, more_JJR experience_NN is_VBZ still_RB needed_VBN to_TO test_VB this_DT new_JJ
          method_NN in_IN practice_NN ._.
        
      
      
        Methods_NNP based_VBN on_IN special_JJ missing_VBG data_NNS models_NNS
        Other_JJ ,_, more_RBR sophisticated_JJ methods_NNS based_VBN on_IN statistical_JJ
        models_NNS are_VBP available_JJ [_NN 16_CD 17_CD 18_CD ]_NN ;_: a_DT technical_JJ review_NN can_MD
        be_VB found_VBN ,_, for_IN example_NN ,_, in_IN [_NN 19_CD ]_NN and_CC [_NN 20_CD ]_NN ._. No_DT general_JJ
        computer_NN programs_NNS are_VBP available_JJ to_TO put_VB them_PRP into_IN effect_NN
        though_IN ,_, because_IN every_DT so-called_JJ informative_JJ missing_VBG data_NNS
        set_VBN requires_VBZ a_DT unique_JJ model_NN to_TO describe_VB it_PRP ._.
      
      
        Methods_NNP based_VBN on_IN ranking_JJ observations_NNS
        A_DT large_JJ class_NN of_IN non-parametric_JJ methods_NNS is_VBZ based_VBN on_IN the_DT
        ranks_VBZ or_CC '_POS scores_NNS '_POS of_IN the_DT observations_NNS instead_RB of_IN the_DT actual_JJ
        values_NNS ._. Commonly_NNP used_VBD non-parametric_JJ methods_NNS in_IN clinical_JJ
        trials_NNS include_VBP the_DT Wilcoxon_NNP signed-rank_JJ test_NN ,_, Mann-_NNP Whitney_NNP
        test_NN ,_, and_CC so_RB on_IN ._. Example_NN 3_CD also_RB used_VBD a_DT ranking_JJ method_NN after_IN
        LOCF_NNP for_IN a_DT secondary_JJ analysis_NN ._. Incorporating_NNP missing_VBG data_NNS
        into_IN these_DT methods_NNS can_MD be_VB easily_RB done_VBN ,_, by_IN ranking_VBG the_DT
        missing_VBG data_NN ,_, according_VBG to_TO the_DT reasons_NNS for_IN withdrawals_NNS [_NN 21_CD
        ]_NN ,_, and_CC ,_, in_IN longitudinal_NN study_NN cases_NNS ,_, the_DT time_NN of_IN
        withdrawal_NN [_NN 22_CD ]_NN ._. For_IN example_NN ,_, death_NN would_MD be_VB given_VBN the_DT
        worst_JJS rank_NN ,_, followed_VBN by_IN '_POS lack_NN of_IN efficacy_NN '_'' ,_, then_RB '_POS adverse_JJ
        reaction_NN '_'' ,_, '_'' patient_NN refusal_NN '_'' ,_, and_CC so_RB on_IN ._. Within_IN the_DT same_JJ
        category_NN of_IN withdrawal_NN ,_, early_JJ dropouts_NNS would_MD be_VB given_VBN worse_JJR
        ranks_NNS than_IN later_JJ dropouts_NNS ._. Ground_NN rules_NNS for_IN the_DT ranking_NN
        should_MD be_VB set_VBN prior_RB to_TO unmasking_VBG the_DT treatment_NN codes_NNS for_IN
        data_NNS analyses_NNS to_TO avoid_VB being_VBG post-hoc_JJ ._. After_IN missing_VBG data_NNS
        are_VBP replaced_VBN by_IN their_PRP$ ranks_NNS ,_, the_DT usual_JJ testing_NN procedure_NN
        can_MD be_VB carried_VBN out_RP ._. One_CD major_JJ drawback_NN in_IN these_DT methods_NNS is_VBZ
        that_IN they_PRP do_VBP not_RB provide_VB any_DT estimation_NN of_IN the_DT treatment_NN
        effect_NN in_IN the_DT original_JJ measurement_NN unit_NN ,_, because_IN the_DT data_NNS
        are_VBP replaced_VBN by_IN the_DT ranks_NNS ._.
        All_DT these_DT methods_NNS ,_, parametric_JJ or_CC non-parametric_JJ ,_, require_VB
        much_RB closer_JJR collaboration_NN between_IN medical_JJ investigators_NNS and_CC
        statisticians_NNS ._. In_IN the_DT parametric_JJ case_NN ,_, the_DT observed_VBN outcome_NN
        cannot_NN provide_VB statistical_JJ tests_NNS to_TO select_VB the_DT missing_VBG data_NN
        models_NNS ._. In_IN both_DT cases_NNS ,_, the_DT validity_NN of_IN the_DT various_JJ models_NNS
        or_CC ranking_JJ rules_NNS requires_VBZ an_DT examination_NN of_IN the_DT missing_VBG
        data_NN information_NN and_CC strong_JJ faith_NN in_IN the_DT reasons_NNS given_VBN for_IN
        the_DT patients_NNS '_POS withdrawal_NN ._. Still_RB ,_, the_DT main_JJ issue_NN is_VBZ the_DT
        question_NN that_IN these_DT methods_NNS are_VBP addressing_VBG ._. They_PRP attempt_VBP to_TO
        follow_VB the_DT ITT_NNP principle_NN (_( but_CC with_IN missing_VBG data_NNS )_) to_TO answer_VB
        question_NN (_( i_NNP )_) above_IN ,_, hoping_VBG that_IN the_DT dropouts_NNS can_MD
        hypothetically_RB be_VB removed_VBN by_IN ,_, say_VB ,_, a_DT truly_RB ITT_NNP design_NN ,_, or_CC
        by_IN successfully_RB using_VBG concurrent_JJ treatments_NNS for_IN intolerable_JJ
        side_NN effects_NNS without_IN affecting_VBG the_DT efficacy_NN of_IN the_DT study_NN
        medication_NN ._.
      
      
        Composite_NN comparisons_NNS
        Many_JJ believe_VBP that_IN removing_VBG the_DT patient_NN 's_POS dropout_NN process_NN
        is_VBZ not_RB plausible_JJ in_IN clinical_JJ practice_NN ._. In_IN this_DT case_NN ,_, the_DT
        dropout_NN process_NN itself_PRP may_MD be_VB an_DT outcome_NN of_IN interest_NN and_CC
        not_RB a_DT nuisance_JJ effect_NN ._. For_IN example_NN ,_, the_DT US_NNP Federal_NNP Drug_NNP
        Association_NNP 's_POS draft_NN guidance_NN on_IN diabetes_NN trials_NNS
        specifically_RB requested_VBD the_DT consideration_NN of_IN dropouts_NNS as_IN an_DT
        endpoint_NN [_NN 23_CD ]_NN ._. Therefore_RB ,_, the_DT problem_NN becomes_VBZ a_NNP
        '_POS composite_JJ endpoints_NNS '_POS issue_NN ._. This_DT is_VBZ the_DT approach_NN taken_VBN in_IN
        [_NN 24_CD 25_CD ]_NN ,_, and_CC it_PRP has_VBZ lately_RB been_VBN extended_VBN to_TO modeling_VBG the_DT
        joint_JJ distribution_NN of_IN the_DT longitudinal_NN and_CC time-to-event_JJ
        data_NNS (_( ie_NN ,_, time_NN to_TO withdrawal_NN )_) [_NN 26_CD 27_CD ]_NN ._. In_IN this_DT setting_NN ,_,
        we_PRP would_MD compare_VB the_DT treatment_NN groups_NNS with_IN two_CD aspects_NNS
        simultaneously_RB :_: (_( a_DT )_) the_DT chance_NN (_( or_CC duration_NN )_) of_IN complying_VBG
        with_IN the_DT prescribed_VBN protocol_NN and_CC ,_, (_( b_SYM )_) the_DT outcome_NN measure_NN
        (_( eg_NN ,_, mean_VB change_NN in_IN systolic_JJ blood_NN pressure_NN )_) given_VBN the_DT
        pattern_NN of_IN compliance_NN ._. The_DT comparison_NN (_( a_DT )_) is_VBZ
        straightforward_JJ by_IN either_DT the_DT standard_JJ binomial_NN or_CC survival_NN
        techniques_NNS ._. The_DT comparison_NN (_( b_SYM )_) requires_VBZ the_DT same_JJ care_NN as_IN
        has_VBZ been_VBN discussed_VBN here_RB previously_RB ,_, because_RB ,_, given_VBN the_DT
        pattern_NN of_IN compliance_NN ,_, the_DT subgroup_NN of_IN patients_NNS has_VBZ already_RB
        been_VBN self-selected_JJ ._. The_DT randomization_NN mechanism_NN used_VBN for_IN
        achieving_VBG comparability_NN between_IN treatment_NN groups_NNS is_VBZ broken_VBN
        by_IN the_DT post-randomization_JJ stratification_NN of_IN compliance_NN ._. It_PRP
        is_VBZ then_RB important_JJ to_TO check_VB the_DT key_JJ outcome-correlated_JJ
        baseline_NN characteristics_NNS between_IN the_DT treatment_NN groups_NNS for_IN
        any_DT incomparability_NN among_IN these_DT subgroup_NN patients_NNS ._. This_DT was_VBD
        done_VBN in_IN Example_NN 4_CD but_CC not_RB others_NNS ._. Recognizing_NNP that_IN the_DT
        subgroups_NNS are_VBP no_DT longer_RB randomized_JJ ,_, we_PRP should_MD treat_VB this_DT
        portion_NN as_IN a_DT semi-observational_JJ study_NN imbedded_JJ in_IN the_DT
        randomized_JJ trial_NN ._. Techniques_NNP used_VBD for_IN analyzing_VBG
        observational_NN studies_NNS should_MD be_VB applied_VBN to_TO this_DT part_NN of_IN
        comparison_NN [_NN 28_CD ]_NN ._. Generally_RB speaking_VBG ,_, in_IN an_DT observational_NN
        study_NN ,_, bias_NN can_MD only_RB be_VB reduced_VBN but_CC not_RB entirely_RB eliminated_VBN
        by_IN methods_NNS of_IN adjustment_NN or_CC matching_VBG ._. Sensitivity_NNP analysis_NN
        in_IN this_DT approach_NN is_VBZ to_TO consider_VB different_JJ baseline_NN
        covariates_NNS for_IN matching_VBG or_CC adjustment_NN ._.
      
      
        Conclusion_NNP
        The_DT issue_NN of_IN what_WP to_TO do_VB about_IN missing_VBG data_NNS caused_VBN by_IN
        dropouts_NNS in_IN clinical_JJ trials_NNS is_VBZ a_DT research_NN topic_NN that_WDT is_VBZ
        still_RB under_IN development_NN in_IN statistical_JJ literature_NN ._. As_IN has_VBZ
        been_VBN noted_VBN in_IN the_DT ICH-E_NNP 9_CD guideline_NN [_NN 9_CD ]_NN ,_, '_'' no_DT universally_RB
        applicable_JJ methods_NNS of_IN handling_VBG missing_VBG values_NNS can_MD be_VB
        recommended_VBN ._. '_POS The_DT issue_NN of_IN handling_VBG missing_VBG data_NNS is_VBZ
        intrinsically_RB difficult_JJ because_IN it_PRP requires_VBZ a_DT large_JJ
        proportion_NN of_IN missing_VBG data_NNS to_TO investigate_VB a_DT method_NN ._. On_IN the_DT
        other_JJ hand_NN ,_, a_DT large_JJ proportion_NN of_IN missing_VBG data_NNS would_MD make_VB a_DT
        clinical_JJ study_NN less_RBR credible_JJ ._. The_DT best_JJS available_JJ advice_NN is_VBZ
        to_TO minimize_VB the_DT chance_NN of_IN dropouts_NNS at_IN the_DT design_NN stage_NN and_CC
        during_IN trial_NN monitoring_NN ._. A_DT truly_RB ITT_NNP design_NN is_VBZ absolutely_RB
        encouraged_VBN ._. This_DT requires_VBZ follow-up_JJ data_NNS to_TO be_VB collected_VBN
        even_RB after_IN patients_NNS discontinue_VB the_DT treatment_NN ,_, whenever_WRB the_DT
        clinical_JJ status_NN of_IN the_DT patient_NN permits_NNS ._. If_IN it_PRP is_VBZ
        anticipated_VBN that_IN there_EX will_MD be_VB many_JJ dropouts_NNS ,_, then_RB perhaps_RB
        the_DT study_NN 's_POS duration_NN should_MD be_VB shortened_VBN ._. Alternatively_RB ,_,
        the_DT medical_JJ procedure_NN that_WDT is_VBZ deemed_VBN to_TO be_VB the_DT most_RBS likely_JJ
        cause_NN of_IN patients_NNS '_POS withdrawal_NN should_MD be_VB altered_VBN ._. All_DT data_NNS
        after_IN death_NN of_IN any_DT cause_NN should_MD be_VB given_VBN a_DT value_NN of_IN zero_CD
        instead_RB of_IN a_DT blank_NN ._. Consideration_NNP may_MD also_RB be_VB given_VBN to_TO
        define_VB an_DT endpoint_NN (_( event_NN )_) ,_, instead_RB of_IN a_DT measurement_NN value_NN ,_,
        as_IN the_DT primary_JJ response_NN variable_NN ,_, which_WDT can_MD be_VB determined_VBN
        even_RB if_IN the_DT patient_NN withdraws_NNS from_IN the_DT study_NN ._. In_IN an_DT
        analysis_NN ,_, one_PRP should_MD be_VB clear_JJ about_IN the_DT question_NN or_CC
        objective_NN of_IN the_DT analysis_NN with_IN missing_VBG data_NNS ,_, and_CC conduct_NN
        sensitivity_NN analysis_NN with_IN a_DT set_NN of_IN plausible_JJ ,_, pre-specified_JJ
        models_NNS of_IN the_DT missing_VBG data_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        BP_NNP =_SYM blood_NN pressure_NN ;_: HCTZ_NNP =_SYM hydrochlorothiazide_NN ;_: DBP_NNP =_SYM
        diastolic_JJ blood_NN pressure_NN ;_: ITT_NNP =_SYM intent_NN to_TO treat_VB ;_: MCAR_NNP =_SYM
        missing_VBG completely_RB at_IN random_JJ ;_: ICH_NNP =_SYM International_NNP
        Conference_NNP on_IN Harmonization_NNP ;_: LOCF_NNP
        last-observation-carried-forward_JJ ;_: PMI_NNP =_SYM proper_JJ multiple_JJ
        imputation_NN ;_: MAR_NNP =_SYM missing_VBG at_IN random_JJ ;_: PI_NNP =_SYM partial_JJ
        imputation_NN ._.
      
    
  
